Immunome Inc.IMNM
Oncology5 cited findings · profile updated 2026-08-20
29.82 USDnot live — refreshed daily
About Immunome Inc.
Immunome Inc. (IMNM) is an oncology research site. The company's portfolio includes Varegacestat, which is currently under review in the United States with a PDUFA target action date of April 28, 2027. In the RINGSIDE trial, Varegacestat demonstrated a confirmed objective response rate of 56%, compared to 9% for placebo, with a p-value of <0.0001.
Another drug in Immunome's pipeline is IM-1617, which is in Phase 1 development.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| PDUFA target action date | April 28, 2027 | Immunome Inc. — SEC 8-K (2026-08-11), p.1 |
| confirmed objective response rate | 56% (Varegacestat (RINGSIDE trial)) vs 9% (placebo) | Immunome Inc. — SEC 8-K (2026-08-11), p.2 |
| p-value for confirmed objective response rate | <0.0001 (Varegacestat (RINGSIDE trial)) | Immunome Inc. — SEC 8-K (2026-08-11), p.2 |
| Trial Phase | Phase 1 (IM-1617) | Immunome Inc. — SEC 8-K (2026-08-11), p.1 |
Key projects
- Varegacestat — United States
The PDUFA target action date for Varegacestat in the United States is April 28, 2027.
- IM-1617
IM-1617 is in Phase 1 development.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →